These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 29224935

  • 1. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.
    Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T, Committee of Survey on Infliximab use for Kawasaki diseaseJapan Society of Kawasaki Disease, Tokyo, Japan..
    J Pediatr; 2018 Apr; 195():115-120.e3. PubMed ID: 29224935
    [Abstract] [Full Text] [Related]

  • 2. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
    Ansai H, Masuda H, Nakao H, Nishimura N, Kubota M.
    Pediatr Int; 2022 Jan; 64(1):e15226. PubMed ID: 35831245
    [Abstract] [Full Text] [Related]

  • 3. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
    Nagatomo Y, Muneuchi J, Nakashima Y, Nanishi E, Shirozu H, Watanabe M, Uike K, Nagata H, Hirata Y, Yamamura K, Takahashi Y, Okada S, Suzuki Y, Hasegawa S, Ohga S.
    Int J Cardiol; 2018 Nov 15; 271():317-321. PubMed ID: 30144998
    [Abstract] [Full Text] [Related]

  • 4. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
    Xie LP, Zhao L, Chu C, He L, Liang XC, Sun SN, Zhao QM, Wang F, Cao YY, Lin YX, Zeng ZQ, Wu L, Huang GY, Liu F.
    Zhonghua Er Ke Za Zhi; 2022 Jan 02; 60(1):14-19. PubMed ID: 34986617
    [Abstract] [Full Text] [Related]

  • 5. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.
    Hachiya A, Kobayashi N, Matsuzaki S, Takeuchi Y, Akazawa Y, Shigemura T, Motoki N, Masumoto J, Agematsu K.
    Clin Rheumatol; 2018 Jul 02; 37(7):1937-1943. PubMed ID: 29302828
    [Abstract] [Full Text] [Related]

  • 6. Infliximab as an alternative therapy for refractory adult onset Kawasaki disease: A case report.
    Kawaguchi T, Rikitake Y, Tsuruda T, Kawata C, Rikitake M, Iwao K, Aizawa A, Kariya Y, Matsuda M, Miyauchi S, Umekita K, Takajo I, Okayama A.
    Medicine (Baltimore); 2018 Oct 02; 97(40):e12720. PubMed ID: 30290679
    [Abstract] [Full Text] [Related]

  • 7. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 02; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 8. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
    Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK.
    Clin Exp Rheumatol; 2016 Oct 02; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study.
    Takura T, Horiuchi S.
    J Cardiol; 2022 Aug 02; 80(2):172-178. PubMed ID: 35341683
    [Abstract] [Full Text] [Related]

  • 10. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.
    Koizumi K, Hoshiai M, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, Watanabe A, Kagami K, Abe M, Sugita K.
    Pediatr Int; 2018 Sep 02; 60(9):796-802. PubMed ID: 29543362
    [Abstract] [Full Text] [Related]

  • 11. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).
    Miura M, Kobayashi T, Igarashi T, Hamada H, Iwata N, Sasaki Y, Matsukawa M, Sato N, Kubo H, Takei S.
    Pediatr Infect Dis J; 2020 Jan 02; 39(1):41-47. PubMed ID: 31815838
    [Abstract] [Full Text] [Related]

  • 12. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 02; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 13. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 14. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
    Hosoi K, Ohtsuka Y, Fujii T, Kudo T, Matsunaga N, Tomomasa T, Tajiri H, Kunisaki R, Ishige T, Yamada H, Arai K, Yoden A, Ushijima K, Aomatsu T, Nagata S, Uchida K, Takeuchi K, Shimizu T.
    J Gastroenterol Hepatol; 2017 Jan 11; 32(1):114-119. PubMed ID: 27478130
    [Abstract] [Full Text] [Related]

  • 15. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 16. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
    Chen J, Liao J, Xiang L, Zhang S, Yan Y.
    Front Immunol; 2023 May 17; 14():1237670. PubMed ID: 37936712
    [Abstract] [Full Text] [Related]

  • 17. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
    Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, Oonishi T, Hashimoto K, Kobayashi N, Waki K, Suzuki Y, Otsubo Y, Yamada H, Ishikawa C, Kato T, Fuse S.
    Sci Rep; 2018 Jan 31; 8(1):1994. PubMed ID: 29386515
    [Abstract] [Full Text] [Related]

  • 18. Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live Vaccinations.
    Ohnishi Y, Okada S, Kawakami-Miyake A, Furuta T, Fukano R, Yasudo H, Shimokawa M, Hasegawa S.
    Pediatr Infect Dis J; 2022 Sep 01; 41(9):e388-e392. PubMed ID: 35895884
    [Abstract] [Full Text] [Related]

  • 19. Difference in Risk Factors for Subtypes of Acute Cardiac Lesions Resulting from Kawasaki Disease.
    Yamashita M, Ae R, Yashiro M, Aoyama Y, Sano T, Makino N, Nakamura Y.
    Pediatr Cardiol; 2017 Feb 01; 38(2):375-380. PubMed ID: 27878631
    [Abstract] [Full Text] [Related]

  • 20. Development of coronary artery lesions in indolent Kawasaki disease following initial spontaneous defervescence: a retrospective cohort study.
    Takahashi T, Sakakibara H, Morikawa Y, Miura M.
    Pediatr Rheumatol Online J; 2015 Nov 04; 13(1):44. PubMed ID: 26530040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.